Intellia Therapeutics logo

Intellia Therapeutics (NTLA) Q1 2026 Earnings

NTLA·Reported May 11, 2026·Before market open

Intellia Therapeutics reported Q1 2026 revenue of $15.0M (-9.5% YoY), beat analyst consensus of $13.8M by $1.2M. Diluted EPS came in at $-0.81 (+26.4% YoY), beat the $-0.92 consensus by $0.11.

Revenue
$15.0Mbeat by $1.2M
Consensus: $13.8M
Diluted EPS
$-0.81beat by $0.11
Consensus: $-0.92
SEC

SEC Filings

Earnings release8-K · 0001193125-26-215721
Quarterly report10-Q · 0001193125-26-215740

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Intellia Therapeutics's Q1 2026 earnings report.

Intellia Therapeutics (NTLA) reported Q1 2026 earnings on May 11, 2026 before market open.

Intellia Therapeutics reported revenue of $15.0M and diluted EPS of $-0.81 for Q1 2026.

Revenue beat the consensus estimate of $13.8M by $1.2M. EPS beat the consensus estimate of $-0.92 by $0.11.

Compared to the same quarter a year prior, revenue declined 9.5% from $16.6M a year earlier and diluted EPS grew 26.4% from $-1.10.

You can read the 8-K earnings release (0001193125-26-215721) and the 10-Q periodic report (0001193125-26-215740) directly on SEC EDGAR. The filing index links above go to sec.gov.